Insulin derivatives with increased zinc binding
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 24, 2001
Grant Date -
N/A
app pub date -
Jul 25, 1997
filing date -
Jul 26, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Insulin derivatives with increased zinc binding ##STR1## where Z is a histidine residue or a peptide having 2 to 35 genetically encodable amino acid residues, having 1 to 5 histidine residues, are suitable for the production of pharmaceutical preparations for the treatment of diabetes. Insulins of the formula I form complexes with zinc.sup.++, comprising an insulin hexamer and approximately 5 to 9 mol of zinc.sup.++ per hexamer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully